Home>Topics>Companies>Bristol-Myers Squibb

Bristol-Myers Squibb BMY

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Merck follows Bristol with EU green light for immune cancer drug

      Headlines

      Fri, 22 May 2015

      May 22 (Reuters) - European regulators have recommended approval of Merck & Co Inc's immune system-boosting cancer drug Keytruda, following a similar green light last month for Bristol - Myers Squibb Co 's rival product Opdivo.

    2. 4 Companies Leading the Next Wave of Cancer-Drug Innovation

      Video Reports

      Thu, 21 May 2015

      front of the leadership pack is [TICKER: BMY ] Bristol - Myers ( BMY ). Along with Bristol , there's Merck (MRK), [TICKER:RHHBY ..... for growth for pharmaceutical firms and that Bristol - Myers and Merck look like some of the best investment

      Bristol Myers found at 0:54, 4:39

      definitely some leaders. I'd say at the front of the leadership pack is [TICKER: BMY ] Bristol - Myers ( BMY ). Along with Bristol , there's Merck (MRK), [TICKER:RHHBY] Roche (RHHBY), and [TICKER:AZN] AstraZeneca (AZN) as well. So, those are the four names that we see as really leading this next wave of innovation in immuno-oncology. Coffina: Of those four, Bristol is the most concentrated on immuno-oncology as well, right? Conover: Yeah. If you look at Bristol's pipeline, it's almost exclusively focused on immuno-oncology. They have some other assets there, and they obviously have a lot of products they sell currently that aren't in immuno-oncology, but the purest play in immuno-oncology is definitely Bristol . Coffina: Do you feel like investors appreciate this opportunity? Is it already fully baked into stock prices? Conover: This is an important
      think the firms that are best positioned for combination therapy are, again, Bristol --very well positioned--after that Roche and [TICKER:AZN] AstraZeneca are very well positioned. Merck is well in the lead with immuno-oncology but doesn't have quite as many combinations as those other three companies have. Coffina: Great. Thanks for joining me, Damien. Conover: Matt, thanks for having me. Coffina: So, in conclusion, we think immuno-oncology is a particularly promising area for growth for pharmaceutical firms and that Bristol - Myers and Merck look like some of the best investment opportunities. [TICKER:AZN] AstraZeneca and Roche are also toward the forefront of developing these drugs.
    3. Strong ASCO Data Supports Our Above-Consensus IO Sales Projections; Merck Looks Most Undervalued

      Commentary

      Thu, 14 May 2015

      reinforces our wide economic moats for Bristol - Myers , Roche, Merck, and AstraZeneca ..... leading IO group, but Roche and Bristol also look undervalued partially ..... Cancer Research meeting, Roche and Bristol previewed strong data for ASCO

    4. Bristol , AbbVie drug extends multiple myeloma remission-study

      Headlines

      Wed, 13 May 2015

      May 13 (Reuters) - The addition of an experimental Bristol - Myers Squibb biotech medicine to standard therapy for patients whose multiple myeloma has relapsed led to longer remissions and cut the risk

    5. U.S. top court rejects hepatitis B drug patent case

      Headlines

      Mon, 4 May 2015

      WASHINGTON, May 4 (Reuters) - The U.S. Supreme Court on Monday brought to an end Bristol - Myers Squibb Co 's attempt to revive patent protection for its Baraclude treatment for hepatitis B.

    6. Fitch Rates Bristol-Myers Squibb's Euro Bond Issuance 'A-'

      Headlines

      Thu, 30 Apr 2015

      Fitch Ratings has assigned an 'A-' rating to Bristol - Myers Squibb Co .'s ( Bristol - Myers , Bristol , BMY ) Euro Bond issuance. The net proceeds from the ..... press release. KEY RATING DRIVERS --Fitch expects Bristol -Myer

    7. Bayer says Xarelto isn't losing U.S. market share to Eliquis

      Headlines

      Thu, 30 Apr 2015

      FRANKFURT, April 30 (Reuters) - Bayer brushed off concern that its stroke prevention pill Xarelto may be losing market share to rival Bristol - Myers Squibb 's Eliquis in the United States.

    8. RPT-Strong Merck cancer drug sales upstage rival Bristol - Myers

      Headlines

      Wed, 29 Apr 2015

      April 28 (Reuters) - Investors betting that Bristol - Myers Squibb will emerge as the leading player in a hot new class of cancer drugs hit the pause button on Tuesday as a rival therapy from Merck & Co showed much higher sales.

    9. Strong Merck cancer drug sales upstage rival Bristol - Myers

      Headlines

      Tue, 28 Apr 2015

      April 28 (Reuters) - Investors betting that Bristol - Myers Squibb will emerge as the leading player in a hot new class of cancer drugs hit the pause button on Tuesday as a rival therapy from Merck & Co showed much higher sales.

    10. UPDATE 2-High-profile Bristol cancer drug disappoints, shares off

      Headlines

      Tue, 28 Apr 2015

      April 28 (Reuters) - Bristol - Myers Squibb Co on Tuesday reported first-quarter sales of its new cancer immunotherapy Opdivo that were about half of those for a rival medicine from Merck & Co, and its shares fell 2 percent.

    « Prev12345Next »
    Content Partners